ERIS Lifesciences Ltd - ERIS LIFESCIENCE Share Price

Sector: Pharmaceuticals | ISIN: INE406M01024
₹ 885.25 (-2.47%) icon23 May, 2024, 12:00:00 AM
Open
₹ 907.95
Prev. Close
₹ 907.70
Turnover(lac)
₹ 0.03
Day's High
₹ 908.30
Day's Low
₹ 882.50
52 Wk High
₹ 971.90
52 Wk Low
₹ 610.60
Book Value
₹ 185.35
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 12,043.60
P/E
40.15
EPS
22.03
Div. Yield
0.00

ERIS Lifesciences Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/23/2024 12:00:00 AM

    ₹ 885.25 -22.45 -2.47
  • Open
  • ₹ 907.95
  • Prev. Close
  • ₹ 907.7
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 908.3
  • Day's Low
  • ₹ 882.5
  • 52 Week's High
  • ₹ 971.9
  • 52 Week's Low
  • ₹ 610.6
  • Book Value
  • ₹ 185.35
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 12,043.6
  • P/E
  • 40.15
  • EPS
  • 22.03
  • Divi. Yield
  • 0

ERIS Lifesciences Ltd Corporate Actions

14 May , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

14 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Feb , 2024

12:00 AM

01 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Nov , 2023

12:00 AM

07 Aug , 2023

12:00 AM

AGM

Announcement date: 07 Aug , 2023

View Details

31 Jul , 2023

12:00 AM

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 Sep , 2023

12:00 AM

BookCloser

View Details

No Record Found


ERIS Lifesciences Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

ERIS Lifesciences Ltd SHAREHOLDING SNAPSHOT
23 May , 2024 | 10:07 PM

PROMOTER - TOTAL54.90%

Indian: 54.90%

Foreign: 0%

NON-PROMOTER - TOTAL 45.10%

Institutions: 29.90%

Non-Institutions: 15.19%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

ERIS Lifesciences Ltd FINANCIALS

View Profit & Loss Graph

ERIS Lifesciences Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT ERIS Lifesciences Ltd

  • Amit Indubhushan Bakshi
  • CMD & Executive Director
  • Kaushal Kamlesh Shah
  • WTD & Executive Director
  • Inderjeet Singh Negi
  • WTD & Executive Director
  • Krishnakumar Vaidyanathan
  • Executive Director / WTD / Chi
  • Sujesh Vasudevan
  • Independent Non Exe. Director
  • Prashant Gupta
  • Independent Non Exe. Director
  • Rajeev Narotam Dalal
  • Independent Non Exe. Director
  • Kalpana Unadkat
  • Independent Non Exe. Director

Summary

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to Eris Lifesciences Private Limited on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to Eris Lifesciences Limited on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.In 2007, the company launched Eris division focused on cardiology and diabetes segment. In 2008, the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009, the company launched Adura division focused on cardiology and diabetes... Read More


Reports by ERIS Lifesciences Ltd


Reports by ERIS Lifesciences Ltd

Company FAQ

No Record Found